{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:40:40Z","timestamp":1790116840592,"version":"4.0.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It remains unclear which adjunctive drug for Parkinson\u2019s disease (PD) in combination with levodopa is more effective, tolerable, and safe. We aimed to compare the efficacy, tolerability, and safety among anti-PD drugs from several classes in patients with fluctuating PD who received levodopa through network meta-analysis (NMA). Twelve anti-PD drugs belonging to 4 different drug classes (dopamine agonists, monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, and an adenosine A2A receptor antagonist) were selected. We systematically searched PubMed, Embase, and the Cochrane Library for eligible randomized controlled trials (RCTs) comparing placebo with anti-PD drug or among anti-PD drugs in patients with PD who experienced motor fluctuations or wearing-off and received levodopa. We included 54 RCTs in the analysis. The NMA was performed under a frequentist framework using a random-effects model. The efficacy outcome was change in daily off-time, and the tolerability outcome was discontinuation due to all causes. Safety outcomes included discontinuation due to adverse events (AEs) and the incidence of AEs, dyskinesia, hallucination, and orthostatic hypotension. According to the surface under the cumulative ranking curve (SUCRA) in the NMA, ropinirole transdermal patch (SUCRA, 0.861) ranked the highest in efficacy, followed by pramipexole (0.762), ropinirole extended release (ER) (0.750), and safinamide (0.691). In terms of tolerability, ropinirole (0.954) ranked the highest, followed by pramipexole (0.857), safinamide (0.717), and ropinirole ER (0.708). Each anti-PD drug had different SUCRA ranking profiles for the safety outcomes. These findings suggest that ropinirole, pramipexole, and safinamide are well-balanced anti-PD drugs that satisfy both efficacy and tolerability outcomes.<\/jats:p>","DOI":"10.1038\/s41531-023-00589-8","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T03:28:24Z","timestamp":1697686104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson\u2019s disease - network meta-analysis"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-2486","authenticated-orcid":false,"given":"Wataru","family":"Sako","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8120-3971","authenticated-orcid":false,"given":"Yuki","family":"Kogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Koebis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0642-4555","authenticated-orcid":false,"given":"Yoshiaki","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yamakage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-2556","authenticated-orcid":false,"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"589_CR1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. Lancet (London, England). 386, 896\u2013912 (2015).","journal-title":"Lancet (London, England)."},{"key":"589_CR2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of Parkinson disease: a review. JAMA. 323, 548\u2013560 (2020).","journal-title":"JAMA."},{"key":"589_CR3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nrd.2018.136","volume":"17","author":"D Charvin","year":"2018","unstructured":"Charvin, D., Medori, R., Hauser, R. A. & Rascol, O. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat. Rev. Drug Discov. 17, 804\u2013822 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"589_CR4","unstructured":"Chaimani, A. et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). (Cochrane, 2022). https:\/\/training.cochrane.org\/handbook (accessed 17 Jun 2022)."},{"key":"589_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/srep45865","volume":"8","author":"C Zhuo","year":"2017","unstructured":"Zhuo, C. et al. Comparison for efficacy and tolerability among ten drugs for treatment of Parkinson\u2019s disease: a network meta-analysis. Sci. Rep. 8, 45865, https:\/\/doi.org\/10.1038\/srep45865 (2017).","journal-title":"Sci. Rep."},{"key":"589_CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000486252","volume":"45","author":"B-D Li","year":"2018","unstructured":"Li, B.-D. et al. Comparison of the efficacy of different drugs on non-motor symptoms of Parkinson\u2019s disease: a network meta-analysis. Cell Physiol. Biochem. 45, 119\u2013130 (2018).","journal-title":"Cell Physiol. Biochem."},{"key":"589_CR7","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1111\/bcp.13651","volume":"84","author":"CD Binde","year":"2018","unstructured":"Binde, C. D., Tvete, I. F., G\u00e5semyr, J., Natvig, B. & Klemp, M. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson\u2019s disease. Br J Clin Pharmacol. 84, 1917\u20131927 (2018).","journal-title":"Br J Clin Pharmacol."},{"key":"589_CR8","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00228-020-02961-6","volume":"76","author":"CD Binde","year":"2020","unstructured":"Binde, C. D., Tvete, I. F., G\u00e5semyr, J. I., Natvig, B. & Klemp, M. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson\u2019s disease: a multiple treatment comparison meta-analysis. Eur. J. Clin. Pharmacol. 76, 1731\u20131743 (2020).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"589_CR9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s12325-019-00938-1","volume":"36","author":"H Zhao","year":"2019","unstructured":"Zhao, H. et al. Indirect comparison of ropinirole and pramipexole as levodopa adjunctive therapy in advanced Parkinson\u2019s disease: a systematic review and network meta-analysis. Adv Ther. 36, 1252\u20131265 (2019).","journal-title":"Adv Ther."},{"key":"589_CR10","doi-asserted-by":"publisher","first-page":"728083","DOI":"10.3389\/fnins.2021.728083","volume":"15","author":"X Ruan","year":"2021","unstructured":"Ruan, X. et al. Comparative efficacy and safety of dopamine agonists in advanced Parkinson\u2019s disease with motor fluctuations: a systematic review and network meta-analysis of double-blind randomized controlled trials. Front. Neurosci. 15, 728083, https:\/\/doi.org\/10.3389\/fnins.2021.728083 (2021).","journal-title":"Front. Neurosci."},{"key":"589_CR11","doi-asserted-by":"publisher","first-page":"707723","DOI":"10.3389\/fneur.2021.707723","volume":"12","author":"Z Song","year":"2021","unstructured":"Song, Z. et al. Different Catechol-O-Methyl transferase inhibitors in Parkinson\u2019s disease: a Bayesian network meta-analysis. Front Neurol. 12, 707723. https:\/\/doi.org\/10.3389\/fneur.2021.707723 (2021).","journal-title":"Front Neurol."},{"key":"589_CR12","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/ene.15651","volume":"30","author":"R Yan","year":"2023","unstructured":"Yan, R. et al. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson\u2019s disease: a network meta-analysis of randomized controlled trials. Eur J Neurol. 30, 1118\u20131134 (2023).","journal-title":"Eur J Neurol."},{"key":"589_CR13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/ene.15635","volume":"30","author":"X-T Chen","year":"2023","unstructured":"Chen, X.-T., Zhang, Q., Wen, S.-Y., Chen, F.-F. & Zhou, C.-Q. Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson\u2019s disease: a network meta-analysis. Eur J Neurol. 30, 762\u2013773 (2023).","journal-title":"Eur J Neurol."},{"key":"589_CR14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mds.21191","volume":"22","author":"P Barone","year":"2007","unstructured":"Barone, P., Lamb, J., Ellis, A. & Clarke, Z. Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson\u2019s disease. Mov. Disord. 22, 483\u2013489 (2007).","journal-title":"Mov. Disord."},{"key":"589_CR15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain, R. et al. Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov. Disord. 29, 229\u2013237 (2014).","journal-title":"Mov. Disord."},{"key":"589_CR16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","volume":"74","author":"DJ Brooks","year":"2003","unstructured":"Brooks, D. J. & Sagar, H. & UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson\u2019s disease: a randomised, placebo controlled, double blind, six month study. J. Neurol. Neurosurg. Psychiatry. 74, 1071\u20131079 (2003).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"589_CR17","unstructured":"A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg\/day KW-6002 (Istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson\u2019s Disease in Patients with Motor Response Complications on Levodopa Therapy. WHO ICTRP identifier: EUCTR2004-000817-20-IT. (Updated September 3, 2012). https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2004-000817-20-IT (accessed17 Jun 2022)."},{"key":"589_CR18","unstructured":"Study to test the safety and effect of an investigational study drug, Istradefylline, in moderate to severe Parkinson\u2019s Disease (PD) patients who have been treated with levodopa combination therapy. WHO ICTRP identifier: EUCTR2013-002254-70-DE. (Updated October 31, 2016) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2013-002254-70-DE (accessed 17 Jun 2022)."},{"key":"589_CR19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00702-002-0799-z","volume":"110","author":"G F\u00e9nelon","year":"2003","unstructured":"F\u00e9nelon, G. et al. Efficacy and tolerability of entacapone in patients with Parkinson\u2019s disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. a randomized, double-blind, multicentre study. J. Neural. Transm. 110, 239\u2013251 (2003).","journal-title":"J. Neural. Transm."},{"key":"589_CR20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/ene.12666","volume":"22","author":"JJ Ferreira","year":"2015","unstructured":"Ferreira, J. J. et al. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson\u2019s disease. Eur. J. Neurol. 22, 815\u2013825 (2015).","journal-title":"Eur. J. Neurol."},{"key":"589_CR21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira, J. J. et al. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 15, 154\u2013165 (2016).","journal-title":"Lancet Neurol."},{"key":"589_CR22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00002826-198802000-00004","volume":"11","author":"LI Golbe","year":"1988","unstructured":"Golbe, L. I. et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson\u2019s disease. Clin. Neuropharmacol. 11, 45\u201355 (1988).","journal-title":"Clin. Neuropharmacol."},{"key":"589_CR23","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1212\/WNL.49.4.1060","volume":"49","author":"M Guttman","year":"1997","unstructured":"Guttman, M. & the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson\u2019s disease. Neurology. 49, 1060\u20131065 (1997).","journal-title":"Neurology."},{"key":"589_CR24","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/mds.28071","volume":"35","author":"N Hattori","year":"2020","unstructured":"Hattori, N. et al. Ropinirole patch versus placebo, ropinirole extended-release tablet in advanced Parkinson\u2019s disease. Mov. Disord. 35, 1565\u20131573 (2020).","journal-title":"Mov. Disord."},{"key":"589_CR25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.parkreldis.2018.04.025","volume":"53","author":"N Hattori","year":"2018","unstructured":"Hattori, N. et al. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson\u2019s disease patients with wearing-off phenomena: a phase 2\/3, randomized, double-blind, placebo-controlled, multicenter study. Parkinsonism Relat. Disord. 53, 21\u201327 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"589_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","volume":"75","author":"N Hattori","year":"2020","unstructured":"Hattori, N., Tsuboi, Y., Yamamoto, A., Sasagawa, Y. & Nomoto, M. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson\u2019s disease: A randomized, double-blind, placebo-controlled, phase II\/III study. Parkinsonism Relat Disord. 75, 17\u201323 (2020).","journal-title":"Parkinsonism Relat Disord."},{"key":"589_CR27","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/mds.22095","volume":"23","author":"RA Hauser","year":"2008","unstructured":"Hauser, R. A. et al. Study of istradefylline in patients with Parkinson\u2019s disease on levodopa with motor fluctuations. Mov. Disord. 23, 2177\u20132185 (2008).","journal-title":"Mov. Disord."},{"key":"589_CR28","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamaneurol.2015.2268","volume":"72","author":"RA Hauser","year":"2015","unstructured":"Hauser, R. A. et al. Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol. 72, 1491\u20131500 (2015).","journal-title":"JAMA Neurol."},{"key":"589_CR29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"AJ Lees","year":"2017","unstructured":"Lees, A. J. et al. Opicapone as adjunct to levodopa therapy in patients With Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 74, 197\u2013206 (2017).","journal-title":"JAMA Neurol."},{"key":"589_CR30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.21315","volume":"63","author":"PA LeWitt","year":"2008","unstructured":"LeWitt, P. A. et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201d time in Parkinson\u2019s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 63, 295\u2013302 (2008).","journal-title":"Ann Neurol."},{"key":"589_CR31","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","volume":"68","author":"PA LeWitt","year":"2007","unstructured":"LeWitt, P. A., Lyons, K. E. & Pahwa, R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 68, 1262\u20131267 (2007).","journal-title":"Neurology."},{"key":"589_CR32","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","volume":"51","author":"A Lieberman","year":"1998","unstructured":"Lieberman, A. et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson\u2019s disease. Neurology. 51, 1057\u20131062 (1998).","journal-title":"Neurology."},{"key":"589_CR33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.49.1.162","volume":"49","author":"A Lieberman","year":"1997","unstructured":"Lieberman, A., Ranhosky, A. & Korts, D. Clinical evaluation of pramipexole in advanced Parkinson\u2019s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 49, 162\u2013168 (1997).","journal-title":"Neurology."},{"key":"589_CR34","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/mds.21313","volume":"22","author":"Y Mizuno","year":"2007","unstructured":"Mizuno, Y. et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson\u2019s disease: STRONG study. Mov Disord. 22, 1860\u20131865 (2007).","journal-title":"Mov Disord."},{"key":"589_CR35","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.23107","volume":"25","author":"Y Mizuno","year":"2010","unstructured":"Mizuno, Y., Hasegawa, K., Kondo, T., Kuno, S. & Yamamoto, M. Clinical efficacy of istradefylline (KW-6002) in Parkinson\u2019s disease: a randomized, controlled study. Mov Disord. 25, 1437\u20131443 (2010).","journal-title":"Mov Disord."},{"key":"589_CR36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21218","volume":"22","author":"Y Mizuno","year":"2007","unstructured":"Mizuno, Y. et al. Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients. Mov. Disord. 22, 75\u201380 (2007).","journal-title":"Mov. Disord."},{"key":"589_CR37","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.25418","volume":"28","author":"Y Mizuno","year":"2013","unstructured":"Mizuno, Y. & Kondo, T. & the Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson\u2019s disease. Mov. Disord. 28, 1138\u20131141 (2013).","journal-title":"Mov. Disord."},{"key":"589_CR38","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.parkreldis.2014.10.005","volume":"20","author":"Y Mizuno","year":"2014","unstructured":"Mizuno, Y. et al. Rotigotine vs ropinirole in advanced stage Parkinson\u2019s disease: a double-blind study. Parkinsonism Relat Disord. 20, 1388\u20131393 (2014).","journal-title":"Parkinsonism Relat Disord."},{"key":"589_CR39","unstructured":"Study of Azilect\u00ae (Rasagiline) in Levodopa-treated Parkinson\u2019s Disease patients with motor fluctuations in Korea. Clinical trial.gov identifier: NCT01268891. (Updated December 3, 2013) https:\/\/clinicaltrials.gov\/show\/NCT01268891 (accessed 17 Jun 2022)."},{"key":"589_CR40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3233\/JPD-130320","volume":"4","author":"AP Nicholas","year":"2014","unstructured":"Nicholas, A. P. et al. A randomized study of rotigotine dose response on \u2018off\u2019 time in advanced Parkinson\u2019s disease. J. Parkinsons Dis. 4, 361\u2013373 (2014).","journal-title":"J. Parkinsons Dis."},{"key":"589_CR41","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00415-014-7427-3","volume":"261","author":"M Nomoto","year":"2014","unstructured":"Nomoto, M. et al. Transdermal rotigotine in advanced Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. J. Neurol. 261, 1887\u20131893 (2014).","journal-title":"J. Neurol."},{"key":"589_CR42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WNF.0b013e3180616570","volume":"30","author":"WG Ondo","year":"2007","unstructured":"Ondo, W. G., Sethi, K. D. & Kricorian, G. Selegiline orally disintegrating tablets in patients with Parkinson disease and \u201cwearing off\u201d symptoms. Clin. Neuropharmacol. 30, 295\u2013300 (2007).","journal-title":"Clin. Neuropharmacol."},{"key":"589_CR43","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","volume":"68","author":"R Pahwa","year":"2007","unstructured":"Pahwa, R. et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 68, 1108\u20131115 (2007).","journal-title":"Neurology."},{"key":"589_CR44","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 62, 241\u2013248 (2005).","DOI":"10.1001\/archneur.62.2.241"},{"key":"589_CR45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","volume":"105","author":"WH Poewe","year":"2002","unstructured":"Poewe, W. H. et al. Efficacy and safety of entacapone in Parkinson\u2019s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol. Scand. 105, 245\u2013255 (2002).","journal-title":"Acta Neurol. Scand."},{"key":"589_CR46","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe, W. H. et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomized controlled trial. Lancet Neurol. 6, 513\u2013520 (2007).","journal-title":"Lancet Neurol."},{"key":"589_CR47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.parkreldis.2011.09.023","volume":"18","author":"E Pourcher","year":"2012","unstructured":"Pourcher, E. et al. Istradefylline for Parkinson\u2019s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat. Disord. 18, 178\u2013184 (2012).","journal-title":"Parkinsonism Relat. Disord."},{"key":"589_CR48","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol, O. et al. Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial. Lancet (London, England). 365, 947\u2013954 (2005).","journal-title":"Lancet (London, England)."},{"key":"589_CR49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00002826-199619030-00005","volume":"19","author":"O Rascol","year":"1996","unstructured":"Rascol, O. et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson\u2019s disease. Clin. Neuropharmacol. 19, 234\u2013245 (1996).","journal-title":"Clin. Neuropharmacol."},{"key":"589_CR50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/WNF.0b013e318241520b","volume":"35","author":"O Rascol","year":"2012","unstructured":"Rascol, O. et al. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin. Neuropharmacol. 35, 15\u201320 (2012).","journal-title":"Clin. Neuropharmacol."},{"key":"589_CR51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0404.2004.00363.x","volume":"111","author":"H Reichmann","year":"2005","unstructured":"Reichmann, H. et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta. Neurol. Scand. 111, 21\u201328 (2005).","journal-title":"Acta. Neurol. Scand."},{"key":"589_CR52","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","volume":"77","author":"AHV Schapira","year":"2011","unstructured":"Schapira, A. H. V. et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 77, 767\u2013774 (2011).","journal-title":"Neurology."},{"key":"589_CR53","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","volume":"74","author":"AHV Schapira","year":"2017","unstructured":"Schapira, A. H. V. et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 74, 216\u2013224 (2017).","journal-title":"JAMA Neurol."},{"key":"589_CR54","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000313834.22171.17","volume":"70","author":"M Stacy","year":"2008","unstructured":"Stacy, M. et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 70, 2233\u20132240 (2008).","journal-title":"Neurology."},{"key":"589_CR55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/mds.28322","volume":"36","author":"A Takeda","year":"2021","unstructured":"Takeda, A. et al. Randomized, controlled study of opicapone in Japanese Parkinson\u2019s patients with motor fluctuations. Mov Disord. 36, 415\u2013423 (2021).","journal-title":"Mov Disord."},{"key":"589_CR56","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mds.20036","volume":"19","author":"CH Waters","year":"2004","unstructured":"Waters, C. H. et al. Zydis selegiline reduces off time in Parkinson\u2019s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord. 19, 426\u2013432 (2004).","journal-title":"Mov. Disord."},{"key":"589_CR57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/nmt-2016-0038","volume":"7","author":"TA Zesiewicz","year":"2017","unstructured":"Zesiewicz, T. A. et al. A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson\u2019s disease. Neurodegener. Dis. Manag. 7, 61\u201372 (2017).","journal-title":"Neurodegener. Dis. Manag."},{"key":"589_CR58","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1017\/S1461145713000175","volume":"16","author":"L Zhang","year":"2013","unstructured":"Zhang, L. et al. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson\u2019s disease: a randomized, double-blind, parallel-controlled, multi-centre trial. Int. J. Neuropsychopharmacol. 16, 1529\u20131537 (2013).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"589_CR59","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.parkreldis.2017.08.015","volume":"44","author":"Z-X Zhang","year":"2017","unstructured":"Zhang, Z.-X. et al. Rotigotine transdermal patch in Chinese patients with advanced Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled pivotal study. Parkinsonism Relat. Disord. 44, 6\u201312 (2017).","journal-title":"Parkinsonism Relat. Disord."},{"key":"589_CR60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40035-018-0119-7","volume":"7","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z. et al. Adjunct rasagiline to treat Parkinson\u2019s disease with motor fluctuations: a randomized, double-blind study in China. Transl. Neurodegener. 7, 14 (2018).","journal-title":"Transl. Neurodegener."},{"key":"589_CR61","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.parkreldis.2013.07.009","volume":"19","author":"Z Zhang","year":"2013","unstructured":"Zhang, Z. et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson\u2019s disease: a multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism Relat Disord. 19, 1022\u20131026 (2013).","journal-title":"Parkinsonism Relat Disord."},{"key":"589_CR62","unstructured":"Rotigotine transdermal patch common technical documents for drug application in Japan. https:\/\/www.pmda.go.jp\/drugs\/2012\/P201200165\/index.html"},{"key":"589_CR63","unstructured":"Rotigotine (Neupro) (Transdermal Patch) Common Drug Review in Canada; APPENDIX 6 SUMMARY OF SUPPORTIVE STUDIES. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK409668\/"},{"key":"589_CR64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt, G. H. et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles\u2014continuous outcomes. J. Clin. Epidemiology. 66, 173\u2013183 (2013).","journal-title":"J. Clin. Epidemiology."},{"key":"589_CR65","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/mdc3.13094","volume":"7","author":"P Vokurka","year":"2020","unstructured":"Vokurka, P. et al. Opicapone efficacy and tolerability in Parkinson\u2019s disease patients reporting insufficient benefit\/failure of entacapone. Mov. Disord. Clin. Pract. 7, 955\u2013960 (2020).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"589_CR66","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1136\/jnnp-2020-BNPA.21","volume":"91","author":"R Cole","year":"2020","unstructured":"Cole, R. & Saha, R. The dopaminergic balancing act: a literature review of a novel COMT inhibitor opicapone with a focus on the risk of visual hallucinations. J. Neurol. Neurosurg. Psychiatry. 91, e9 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"589_CR67","first-page":"29","volume":"11","author":"LA Kauppila","year":"2021","unstructured":"Kauppila, L. A., Silva, D. P. & Ferreira, J. J. Clinical Utility of opicapone in the management of Parkinson\u2019s disease: a short review on emerging data and place in therapy. Degener Neurol. Neuromuscul. Dis. 11, 29\u201340 (2021).","journal-title":"Degener Neurol. Neuromuscul. Dis."},{"key":"589_CR68","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2015","unstructured":"Garcia-Ruiz, P. J. et al. Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J. Neurol. Neurosurg. Psychiatry. 85, 840\u2013844 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"589_CR69","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.25291","volume":"28","author":"J Bastiaens","year":"2013","unstructured":"Bastiaens, J., Dorfman, B. J., Christos, P. J. & Nirenberg, M. J. Prospective cohort study of impulse control disorders in Parkinson\u2019s disease. Mov. Disord. 28, 327\u2013333 (2013).","journal-title":"Mov. Disord."},{"key":"589_CR70","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/ene.13034","volume":"23","author":"A Rizos","year":"2016","unstructured":"Rizos, A. et al. A European multicentre survey of impulse control behaviours in Parkinson\u2019s disease patients treated with short- and long-acting dopamine agonists. Eur. J. Neurol. 23, 1255\u20131261 (2016).","journal-title":"Eur. J. Neurol."},{"key":"589_CR71","doi-asserted-by":"crossref","first-page":"100257","DOI":"10.1016\/j.ensci.2020.100257","volume":"20","author":"M Suzuki","year":"2020","unstructured":"Suzuki, M., Arai, M., Hayashi, A. & Ogino, M. Prescription pattern of anti-Parkinson\u2019s disease drugs in Japan based on a nationwide medical claims database. eNeurologicalSci. 20, 100257 (2020).","journal-title":"eNeurologicalSci."},{"key":"589_CR72","doi-asserted-by":"crossref","first-page":"1162016","DOI":"10.3389\/fneur.2023.1162016","volume":"14","author":"M Seki","year":"2023","unstructured":"Seki, M., Kawata, Y., Hayashi, A., Arai, M. & Fujimoto, S. Prescribing patterns and determinants for elderly patients with Parkinson\u2019s disease in Japan: a retrospective observational study using insurance claims databases. Front Neurol. 14, 1162016 (2023).","journal-title":"Front Neurol."},{"key":"589_CR73","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","volume":"74","author":"R Pahwa","year":"2017","unstructured":"Pahwa, R. et al. ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID Study) a randomized clinical trial. JAMA Neurol. 74, 941\u2013949 (2017).","journal-title":"JAMA Neurol."},{"key":"589_CR74","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","volume":"32","author":"W Oertel","year":"2017","unstructured":"Oertel, W. et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease. Mov. Disord. 32, 1701\u20131709 (2017).","journal-title":"Mov. Disord."},{"key":"589_CR75","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41531-022-00291-1","volume":"8","author":"RA Hauser","year":"2022","unstructured":"Hauser, R. A., Lytle, J., Formella, A. E. & Tanner, C. M. Amantadine delayed release\/extended release capsules significantly reduce OFF time in Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 29 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"589_CR76","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti, G., Ades, A. E. & Ioannidis, J. P. A. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64, 163\u2013171 (2011).","journal-title":"J. Clin. Epidemiol."},{"key":"589_CR77","volume":"6","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw, L. et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst. Rev. 6, 79 (2017).","journal-title":"Syst. Rev."},{"key":"589_CR78","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton, B. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 162, 777\u2013784 (2015).","journal-title":"Ann. Intern. Med."},{"key":"589_CR79","doi-asserted-by":"publisher","first-page":"14898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 366, 14898. https:\/\/doi.org\/10.1136\/bmj.l4898 (2019).","journal-title":"BMJ."},{"key":"589_CR80","unstructured":"Higgins, J. P. T. et al. Chapter 8: Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). (Cochrane, 2022). https:\/\/training.cochrane.org\/handbook (accessed 17 Jun 2022)."},{"key":"589_CR81","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P. & Salanti, G. Graphical tools for network meta-analysis in STATA. PLoS One. 8, e76654 (2013).","journal-title":"PLoS One."},{"key":"589_CR82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1536867X0800800102","volume":"8","author":"RJ Harris","year":"2008","unstructured":"Harris, R. J. et al. Metan: fixed- and random-effects meta-analysis. Stata J. 8, 3\u201328 (2008).","journal-title":"Stata J."},{"key":"589_CR83","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JPT Higgins","year":"2012","unstructured":"Higgins, J. P. T. et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res. Synth. Methods. 3, 98\u2013110 (2012).","journal-title":"Res. Synth. Methods."},{"key":"589_CR84","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ. 327, 557\u2013560 (2003).","journal-title":"BMJ."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00589-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00589-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00589-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:04:41Z","timestamp":1700525081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00589-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1038\/s41531-023-00589-8","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"13 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing non-financial interests but the following competing financial interests; W.S. has received honoraria from Eisai Co. Ltd, Kyowa Kirin Co. Ltd, Sumitomo Pharma Co. Ltd, and Takeda Pharmaceutical Co. Ltd; has received research support from Mitsubishi Tanabe Pharma Co. and JSPS KAKENHI. Y.Kogo, M.K., T.I. are employees of Eisai Co., Ltd. Y.Kita provided medical writing support, funded by Eisai Co., Ltd. H.Y. performed statistical analysis, funded by Eisai Co., Ltd. N.H. received personal fees from Meiji Seika Pharma Co., Ltd. during the conduct of the submitted work; grants from Ono Pharmaceutical Co., Ltd., FP Corp., Eisai Co., Ltd., and Nihon Mediphysics Co., Ltd.; personal fees from Sumitomo Dainippon Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Hakko-Kirin Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., FP Corp., Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Nihon Medi-physics Co., Ltd., Novartis Pharma K.K., Biogen Idec Japan Ltd., AbbVie GK, Boston Scientific Japan K.K., Sanofi K.K., Alexion Pharmaceuticals, Inc., Mylan N.V., Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceuticals Co., Inc., and Kao Corp.; and reports donations to the department, endowed research departments and joint collaborative research departments from Sumitomo Dainippon Pharma Co., Ltd., Otsuka Pharmaceutical, Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Hakko-Kirin Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eisai Co., Ltd., GSK K.K., Kissei Pharmaceutical Co. Ltd., Novartis Pharma K.K., Nihon Medi-physics Co., Ltd., Biogen Idec Japan Ltd., AbbVie GK, Medtronic, Inc., Boston Scientific Japan K.K., Ono Pharmaceutical Co., Ltd., Hydrogen Health Medical Labo Co., ABIST Co., Ltd., Daiwa Co., Ltd., Bayer Yakuhin Ltd., Nihon Pharmaceutical Co., Ltd., Asahi Kasei Medical Co., Ltd., MiZ Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co. Ltd., and OHARA Pharmaceutical Co., Ltd. outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}